ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1583 • 2015 ACR/ARHP Annual Meeting

    Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Yashaar Chaichian1, Dina Bassiri2, Imre Noth3, Mary Strek3, Tammy Utset1 and Rekha Vij3, 1Medicine, Section of Rheumatology, University of Chicago Medical Center, Chicago, IL, 2Statistical & Applied Research, ACT, Inc., Iowa City, IA, 3Medicine, Section of Pulmonary/Critical Care, University of Chicago Medical Center, Chicago, IL

    Background/Purpose: Interstitial lung disease (ILD) is recognized as a frequent extra-articular manifestation of rheumatoid arthritis (RA) associated with significant morbidity and mortality. Nevertheless, risk factors…
  • Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting

    Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis

    Javier Narváez1, Milagros Ricse2, Juan José Alegre3, Gloria Albert Espi3, Carmen Gomez Vaquero4, Helena Borrell Paños2, Eulalia Armengol2, Joan Miquel Nolla2, Susana Herrera5 and Maria Molina6, 1Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, 5Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, 6Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
  • Abstract Number: 1452 • 2015 ACR/ARHP Annual Meeting

    Pauciimmune and Immune Mediated Pulmonary Capillaritis in Children

    Jennifer Soares1,2, Gail Deutsch2,3, BreAnna Kinghorn2 and Anne M. Stevens4, 1Pediatric Pulmonary and Sleep Division, Seattle Children's Hospital, Seattle, WA, 2School of Medicine, University of Washington, Seattle, WA, 3Pathology, Seattle Children's Hospital, Seattle, WA, 4Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA

    Background/Purpose: Immune mediated and pauciimmune pulmonary capillaritis are rare causes of diffuse alveolar hemorrhage and associated childhood diffuse lung disease.  As such ideal therapies and…
  • Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting

    Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

    Elizabeth R. Volkmann1, Michael Roth2, Robert Elashoff3, Philip J. Clements1, Daniel E. Furst2, Dinesh Khanna4, Jonathan Goldin5, Donald Tashkin1 and Scleroderma Lung Study II Group, 1Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA, 4Medicine, University of Michigan, Ann Arbor, MI, 5David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…
  • Abstract Number: 1075 • 2015 ACR/ARHP Annual Meeting

    The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)

    Philip J. Clements1, Donald Tashkin1, Michael Roth1, Dinesh Khanna2, Daniel E. Furst3, Chi-hong Tseng1, Elizabeth R. Volkmann1 and Robert Elashoff4, 1Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine, University of Michigan, Ann Arbor, MI, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA

    Background/Purpose: Demonstrate that the course of forced vital capacity (FVC) over 2-years was better in SSc patients with symptomatic ILD treated with oral MMF for…
  • Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting

    A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis

    Peter Schulam1, Colin Ligon2, Robert Wise3, Laura K. Hummers4, Fredrick M. Wigley5 and Suchi Saria1,6, 1Department of Computer Science, Johns Hopkins University, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, 6Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD

    Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
  • Abstract Number: 307 • 2015 ACR/ARHP Annual Meeting

    Screening for Pulmonary Hypertension in the Anti-Synthetase Syndrome; Utility of Four Different Screening Approaches

    Helena Andersson1, Ivar Sjaastad2, Thomas Schwartz2, Torhild Garen3, T. Mogens Aalokken4 and Øyvind Molberg1, 1Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway, 2Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, 3Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Department of Radiology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Pulmonary hypertension (PH) is a feared complication of the anti-synthetase syndrome (ASS) and has previously been reported to occur in 8% of the patients…
  • Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting

    Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease

    Dinesh Khanna1, Carlo Albera2, Aryeh Fischer3, James R. Seibold4, Nader A. Khalidi5, Ganesh Raghu6, Lorinda Chung7, Elena Schiopu1, Dan Chen8 and Eduard Gorina9, 1University of Michigan, Ann Arbor, MI, 2University of Turin, Turin, Italy, 3National Jewish Health and University of Colorado, Denver, CO, 4Scleroderma Research Consultants LLC, Litchfield, CT, 5McMaster University, Hamilton, ON, Canada, 6University of Washington, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 8Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, 9Formerly of InterMune, Brisbane, CA

    Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
  • Abstract Number: 294 • 2015 ACR/ARHP Annual Meeting

    A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease

    Melissa B. Blom1, Chester V. Oddis2, Diane Koontz3 and Rohit Aggarwal4, 1Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in myositis. Clinical trials in myositis-associated ILD (MA-ILD) are lacking due to the absence…
  • Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting

    Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study

    Thomas Frauenfelder1, Anna Winklehner1, Thi Dan Linh Nguyen1, Rucsandra Dobrota2,3, Stephan Baumüller1, Britta Maurer2 and Oliver Distler2, 1Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, 2Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
  • Abstract Number: 2976 • 2014 ACR/ARHP Annual Meeting

    Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice

    Marco Antivalle, Michel Chevallard, Michele Battellino, MariaChiara Ditto, Valentina Varisco, Federica Rigamonti, Alessandra Mutti, Fabiola Atzeni, Alberto Batticciotto and Piercarlo Sarzi-Puttini, Rheumatology, L. Sacco University Hospital, Milano, Italy

    Background/Purpose: interstitial lung disease (RA-ILD) is one of the most serious extraarticular complications of rheumatoid arthritis (RA). Presently, it is not clear which is the…
  • Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting

    Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension

    Elizabeth Volkmann1, Daniel E. Furst2, Rajeev Saggar3, Philip J. Clements4, Bryant Torres5, Lynne Yoder1 and Rajan Saggar1, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of California, Los Angeles, CA, 3Cardiothoracic Surgery, University of Arizona College of Medicine, Phoenix, AZ, 4University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 5Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA

    Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…
  • Abstract Number: 2190 • 2014 ACR/ARHP Annual Meeting

    Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort

    Adela Gallego Flores1, Carmen Carrasco Cubero2, Raul Veroz Gonzalez1, Luz Maria Mellado Narciso1, Tamara Libertad Rodriguez Araya1, Juan Jose Aznar Sánchez1 and Eugenio Chamizo Carmona1, 1Rheumatology, Hospital de Mérida, Mérida, Spain, 2Rheumatology, Hospital de Merida, Mérida, Spain

    Background/Purpose Diffuse interstitial lung disease (ILD) can be associated with connective tissue diseases (CTD), and can increase morbidity and mortality significantly. The predominant patterns of…
  • Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting

    One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study

    Elana J. Bernstein1, Eric R. Peterson2, Joan M. Bathon2 and David J. Lederer2, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Medicine, Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
  • Abstract Number: 1784 • 2014 ACR/ARHP Annual Meeting

    Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis

    Takeshi Shoda, Tohru Takeuchi, Takaaki Ishida, Hideyuki Shiba, Youhei Fujiki, Daisuke Wakura, Shuzo Yoshida, Takuya Kotani, Shigeki Makino and Toshiaki Hanafusa, Department of Internal Medicine (I), Osaka medical college, Osaka, Japan

    Background/Purpose Many patients with interstitial lung disease (ILD) complicated by microscopic polyangiitis (MPA) show a UIP pattern on chest CT. The prognosis is poorer than…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies